Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

Roche, the company to which the treatment is licensed outside ... a gene therapy for ambulatory patients aged 3-7 years old with Duchenne muscular dystrophy. HC Wainwright upgraded Sarepta on ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

“Patient safety and well-being are Roche’s top priority. We will be collaborating closely with EMA and sharing updates as we have them,” the company added. Sarepta (NASDAQ:SRPT) highlighted ...

Roche (RHHBY) sent a letter dated March 31 to the World Duchenne Organization stating the European Medicines Agency requested a temporary ...

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the shares. Roche reported in a letter addressed to the World Duchenne ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in ...

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU officials with data in support of their gene therapy Elevidys ...

Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec-rokl) following a ...

Roche, the company to which the treatment is ... HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range. Analyst Mitchell S.